

REAADS®
Protein C Antigen Test Kit

For *In Vitro* Diagnostic Use

INTENDED USE

An enzyme-linked immunosorbent assay (ELISA) for the quantitative determination of Protein C Antigen in citrated human plasma.

SUMMARY AND EXPLANATION OF THE TEST

Protein C is a vitamin K-dependent protein synthesized primarily by hepatocytes in the liver and plays an important physiologic role in the Protein C Anticoagulant System.^{1,2} Protein C, thrombin from blood clots, and endothelial cells, through complex interactions with other factors of the coagulation cascade, contribute to the maintenance of normal hemostatic mechanisms by down-regulating clot formation and by promoting fibrinolysis. The Protein C Anticoagulant System is activated by the binding of thrombin to thrombomodulin, a transmembrane protein receptor on endothelial cells.³ The thrombin-thrombomodulin binding on endothelial cell membranes activates circulating Protein C. Activated Protein C binds to Protein S on the membrane of endothelial cells or platelets. In this Protein C-Protein S complex, activated Protein C is now capable of inactivating coagulation factors Va and VIIIa, down-regulating clot formation. Activated Protein C also enhances the function of tissue plasminogen activator (TPA) by dissociating this molecule from its inhibitor, plasminogen activator inhibitor-1 (PAI-1), thereby facilitating clot dissolution or fibrinolysis.¹⁻³

Protein C deficiency, either congenital or acquired, may lead to serious thrombotic events such as thrombophlebitis, deep vein thrombosis, or pulmonary embolism.⁴ Patients with a congenital heterozygous deficiency may present with venous thrombosis in young adulthood, while patients with the rare homozygous deficiency present with massive thrombosis (purpura fulminans) during the neonatal period.⁵ The prevalence of Protein C deficiency in the general population has been estimated at 1 in 300. In younger patients (<40-45 years) with recurrent venous thrombosis, the frequency of Protein C deficiencies may be as high as 10 to 15%.⁶⁻⁷ Acquired Protein C deficiency may be seen in liver disease, extensive thrombotic episodes, surgery, oral anticoagulant therapy, antiphospholipid syndrome, etc. A decreased Protein C activity in plasma may be the result of low concentrations and function (type I) or only low function (type II).⁶

The laboratory diagnosis of Protein C deficiency may require both quantitative and qualitative (functional) determinations. Quantitative determinations of Protein C Antigen are based on immunologic procedures such as radial immunodiffusion in gel, Laurell rocket immunoelectrophoresis and enzyme-linked immunosorbent assay (ELISA).^{6,8} ELISA procedures are less labor intensive and offer several advantages including more objective, accurate and reproducible results. In addition, ELISA allows automation with commonly available laboratory instruments.

PRINCIPLE OF THE TEST

The Protein C Antigen assay is a sandwich ELISA. A capture antibody specific for human Protein C is coated to 96-microwell polystyrene plates. Diluted patient plasma is incubated in the wells, allowing any available Protein C to bind to the anti-human Protein C antibody on the microwell surface. The plates are washed to remove unbound proteins and other plasma molecules. Bound Protein C is quantitated using horseradish peroxidase (HRP) conjugated anti-human Protein C detection antibody. Following incubation, unbound conjugate is removed by washing. A chromogenic substrate of tetramethylbenzidine (TMB) and hydrogen peroxide (H₂O₂) is added to develop a colored reaction. The intensity of the color is measured in optical density (O.D.) units with a spectrophotometer at 450nm. Protein C Antigen relative percent concentrations in patient plasma are determined against a curve prepared from the reference plasma provided with the kit.

REAGENTS

Store at 2 - 8°C. Do Not Freeze.

Each REAADS Protein C Antigen 96-microwell Test Kit contains the following reagents:

- 12 x 8 anti-human Protein C antibody coated microwells.
- 60 mL Sample Diluent (blue-green solution); contains sodium azide.
- 3 vials x 0.5 mL lyophilized Reference Plasma, with assay sheet
- 12 mL anti-human Protein C HRP Conjugate (blue solution).
- 13 mL Substrate (TMB and H₂O₂).
- 15 mL Stopping Solution (0.36 N sulfuric acid).
- 30 mL Wash Concentrate (33X phosphate buffered saline with 0.01% Tween 20).

Note: turbidity may appear in wash concentrate which will not affect component performance and should disappear when working dilution is prepared.

WARNINGS AND PRECAUTIONS

For In Vitro Diagnostic Use

1. Human source material used to prepare the reference plasma included in this kit has been tested and shown to be negative for antibodies to HBsAg, HCV, HIV-I and HIV-II by FDA required tests. However, all human blood derivatives, including patient samples, should be handled as potentially infectious material.
2. Do not pipette by mouth.
3. Do not smoke, eat, or drink in areas where specimens or kit reagents are handled.
4. Wear disposable gloves while handling kit reagents and wash hands thoroughly afterwards.
5. One component substrate can cause irritation to the eyes and skin. Absorption through the skin is possible. Use gloves when handling substrate and wash thoroughly after handling. Keep reagent away from ignition sources. Avoid contact with oxidizing agents.
6. Certain components are labeled with the following:
Irritating to eyes (R 36). Avoid contact with skin (S 24). Avoid contact with eyes (S 25). In case of contact with eyes, rinse immediately with plenty of water and seek medical advice (S 26). If swallowed, seek medical advice immediately and show this container or label (S 46).

Warning  . Biological Risk .

SPECIMEN COLLECTION AND PREPARATION

Plasma collected with either 3.2% or 3.8% sodium citrate as an anticoagulant should be used as the sample matrix. Blood should be collected by venipuncture, and the sample centrifuged immediately. Remove the plasma and store at 2 - 8°C until testing can be performed. If not tested within 8 hours of collection, the sample should be stored at -70°C and tested within 1 month.

INSTRUCTIONS FOR USE

Materials Provided

REAADS Protein C Antigen Test Kit; see "Reagents," for a complete listing.

Materials Required but not Supplied

- Protein C Control Plasma. Reconstitute Control Plasma selected for use following manufacturer's instructions, and store as recommended.
- Reagent grade water (1L) to prepare PBS/Tween 20 wash solution, to reconstitute Reference Plasma, and to zero or blank the plate reader during the final assay step.
- Graduated cylinders
- Precision pipettors capable of delivering between 5 and 1000 microliters, with appropriate tips
- Miscellaneous glassware appropriate for small volume handling

- Flask or bottle, 1 liter
- Wash bottles, preferably with the tip partially cut back to provide a wide stream, or an automated or semi-automated washing system
- Disposable gloves, powder-free recommended
- Plate reading spectrophotometer capable of reading absorbance at 450nm (with a 650nm reference if available)
- Multichannel pipettors capable of delivering to 8 wells simultaneously
- Microdilution tubes for patient sample preparation

Procedural Notes

1. Bring plasma samples and kit reagents to room temperature (18 - 26°C) and mix well before using; avoid foaming. Return all unused samples and reagents to refrigerated storage (2 - 8°C) as soon as possible.
2. All dilutions of reference plasma, control plasma selected for use, and patient samples must be made just prior to use in the assay.
3. A single water blank well should be set up on each plate with each run. No sample or kit reagents are to be added to this well. Instead, add 200 µL of reagent grade water to the well immediately prior to reading the plate in the spectrophotometer. The plate reader should be programmed to zero or blank against this water well.
4. Good washing technique is critical for optimal performance of the assay. Adequate washing is best accomplished by directing a forceful stream of wash solution from a plastic squeeze bottle with a wide tip into the bottom of the microwells. Wash solution in the water blank well will not interfere with the procedure. An automated microtiter plate washing system can also be used.
5. **IMPORTANT:** Failure to adequately remove residual PBS/Tween 20 can cause inconsistent color development of the substrate solution.
6. Use a multichannel pipettor capable of delivering to 8 wells simultaneously when possible. This speeds the process and allows for more uniform incubation and reaction times for all wells.
7. Carefully controlled timing of all steps is critical. All reference plasma dilutions, controls and samples must be added within a five minute period. Batch size of samples should not be larger than the amount that can be added within this time period.
8. For all incubations, the start of the incubation period begins with the completion of reagent or sample addition.
9. Addition of all samples and reagents should be performed at the same rate and in the same sequence.
10. Incubation temperatures above or below normal room temperature (18 - 26°C) may contribute to inaccurate results.
11. Avoid contamination of reagents when opening and removing aliquots from the primary vials.
12. Do not use kit components beyond expiration date.
13. Coated microwells, conjugate, and substrate are lot specific components that should not be used with different kit lots.

Reagent preparation

1. Wash Solution – phosphate buffered saline (PBS)/Tween 20: Measure 30 mL Wash Concentrate (33X PBS/Tween 20) and dilute to 1 liter with reagent grade water. The pH of the final solution should be 7.35 ± 0.1 . Store unused PBS/Tween 20 solution at 2 - 8°C. Discard if solution shows signs of contamination.
2. Reconstitute Reference Plasma by adding 0.5 mL reagent grade water. Swirl gently to mix. Allow to stand 10 minutes before use for complete dissolution. Stable for 8 hours when stored at 2 - 8°C. Reconstitute appropriate control plasma following manufacturer's instructions, and store as recommended.

Assay Procedure

1. Remove any microwell strips that will not be used from the frame and store them in the bag provided.
2. Assay each reference plasma dilution in duplicate. Duplicate determinations are also recommended for patient and control samples. One well should be run as a reagent blank; sample diluent without serum is added to the well as explained in step 7 of this section. This well is treated the same as a control or patient sample in subsequent assay steps. A water blank well should be included with each plate; it is to remain empty until 200 μL of reagent grade water is added at the completion of the assay, immediately prior to reading the plate. The water blank well is to be used to zero the plate reader.
3. Pre-dilute all plasmas (1:2 dilution in Sample Diluent) as follows:
Reference plasma: add 100 μL reference plasma to 100 μL Sample Diluent
Control and patient samples: add 20 μL plasma to 20 μL Sample Diluent
 Mix well. These pre-dilutions are utilized in preparing the working dilutions in steps 4 and 5.
4. Using the 1:2 reference plasma dilution from step 3, prepare six working reference dilutions as described below.

Volume Reference Plasma(1:2)		Volume Sample Diluent		*Reference Level
30 μL	+	500 μL	=	150
20 μL	+	500 μL	=	100
15 μL	+	500 μL	=	75
10 μL	+	500 μL	=	50
10 μL	+	1000 μL	=	25
10 μL	+	2000 μL	=	12.5

* Reference level value to be used for constructing reference curve only

5. Prepare working dilutions of control and patient samples by adding 20 μL of prediluted plasma (1:2 dilution from step 3) to 500 μL Sample Diluent. (Note: these dilutions correspond to the 100% reference plasma dilution.)
6. Mix thoroughly, and add 100 μL of the working dilutions (reference plasmas, controls and patient samples) to the appropriate microwells.
7. Add 100 μL of Sample Diluent to the reagent blank well. Leave the water blank well empty.
8. Incubate 40 minutes at room temperature. After the incubation is complete, carefully invert the microwells and dump the sample fluid. Do not allow samples to contaminate other microwells.
9. Wash 4 times with working wash solution (PBS/Tween 20). Each well should be filled with wash solution per wash. Wash solution in the empty well intended to serve as a water blank will not interfere with the procedure. Invert microwells between each wash to empty fluid. Use a snapping motion of the wrist to shake the liquid from the wells. The frame must be squeezed at the center on the top and bottom to retain microwell modules during washing. Blot on absorbent paper to remove residual wash fluid. Do not allow wells to dry out between steps.
10. Add 100 μL Conjugate (blue) to each well (except the water blank well).
11. Incubate for 10 minutes at room temperature. After the incubation is complete, carefully invert the microwells and dump the conjugate solution.
12. Wash 4 times with working wash solution (PBS/Tween 20) as in step 9. Wash solution in the water blank well does not interfere with the procedure. Use a snapping motion to drain the liquid, and blot on absorbent paper after the final wash. Do not allow the wells to dry out.

13. Add 100 μ L Substrate to each well (except for the water blank well) and incubate for 10 minutes at room temperature. Add the substrate to the wells at a steady rate. Blue color will develop in wells with positive samples.
14. Add 100 μ L Stopping Solution (0.36 N sulfuric acid) to each well (except for the water blank well) to stop the enzyme reaction. Be sure to add Stopping Solution to the wells in the same order and at the same rate as the Substrate Solution was added. Blue Substrate will turn yellow and colorless substrate will remain colorless. Do not add Stopping Solution to the water blank well. Instead, add 200 μ L of reagent grade water to the water blank well. Blank or zero the plate reader against the water blank well. Read the O.D. of each well at 450nm, against a 650nm reference filter (if available). For best results, the O.D. values should be measured within 30 minutes after the addition of Stopping Solution.

Results

1. Calculate the mean O.D. for the duplicates of the reference plasma dilutions, controls selected for use, and patient samples.
2. Plot the mean O.D. obtained for each dilution of the reference plasma (x axis) against the corresponding value of the reference level (y axis). A log-log or point-to-point graph is recommended, although a semi-log may also be used.
3. Using the mean O.D., determine the control and patient relative values from the graph, or, alternatively, use linear regression to calculate from the reference curve.
4. To calculate Protein C Antigen levels in % of normal, multiply the control and patient relative values obtained from the reference curve by the assigned value for the REAADS Reference Plasma (see Reference Plasma Assay sheet included in Package Insert).

For example:

Patient relative value (from the reference curve): 40

Reference Plasma assigned value (from Reference Plasma Assay sheet): 105% of normal

Actual patient Protein C Antigen value (as % of normal): $40 \times 1.05 = 42\%$

5. Ensure that all quality control parameters have been met (see Quality Control) before reporting test results.

QUALITY CONTROL

1. The mean O.D. of the reagent blank should be less than 0.1 when the spectrophotometer has been blanked against the water well. Readings greater than 0.1 may indicate possible reagent contamination or inadequate plate washing.
2. Individual O.D.s for the duplicates of the controls or patient samples should be within 20% of the mean O.D. for samples with absorbance readings greater than 0.200.
3. Protein C Antigen values obtained for the controls should be within manufacturer's assigned ELISA ranges. Occasional small deviations outside these ranges may be acceptable.
4. Each laboratory should periodically determine their own reference range for this assay.

EXPECTED VALUES ⁹

Normal Range:

Protein C Antigen values are generally expressed in relative percent (%) as compared to pooled normal plasma. The normal range when normal plasma samples were tested by REAADS Protein C Antigen assay was 72-160% (mean 110%, SD 24%). This range is consistent with normal ranges published in the literature and reported by other commercially available assays.^{6,8} Samples with values above the range of the reference curve may be diluted and retested for accurate results.

PERFORMANCE CHARACTERISTICS ⁹

Detection range:

The detection range for REAADS Protein C Antigen assay has been described as 5 - 200%. However, the effective range of each run will depend on the assayed value of the reference plasma. For greatest accuracy, samples which generate absorbance readings outside the O.D. range of the reference curve should be retested at an appropriate dilution.

Precision:

Intra-assay precision:

To determine variability within a plate, three plasma samples with known Protein C levels (one high, one medium, and one low) were tested in 16 wells by two operators, on six plates from each of three lots. The data, presented in the following table, shows a mean CV of 7.0% across three lots. In addition, ninety-nine (99) patient samples with Protein C levels spanning the entire detection range of the assay were tested in duplicate across 3 lots to demonstrate the precision end users may expect when performing the assay according to package insert instructions. As shown in the table, the overall mean CV for duplicates was 6.0%.

Inter-assay precision:

Six (6) commercially prepared, assayed plasma samples with Protein C values ranging from 39 - 112% were tested in duplicate on three lots to determine assay precision between lots. The mean inter-assay CV was 7.5%, as seen in the table:

Intra-assay Precision (variability within a plate)	Protein C range (% of normal)	CV range (3 pilot lots)	Overall mean CV:
Replicates (x16):	82% - 89%	4.6 - 12.6%	7.0%
	44% - 116%	2.9 - 13.0%	
	37% - 41%	2.9 - 21.7%	
Duplicates:	entire range		6.0%
Inter-assay precision (variability between lots)			
Duplicates:	39% - 112%	1.4 - 10.0%	7.5%

Linearity:

Serial two-fold dilutions of Protein C reference plasma samples tested on three (3) lots of REAADS Protein C Antigen assay demonstrated curves with a mean coefficient of determination (R-squared) of 0.992. Individual point recovery ranged from -15.2 to +21.3%.

Accuracy:

Accuracy was determined by testing mixtures of reference plasma with predetermined values on REAADS Protein C Antigen assay and calculating the recovery of theoretical values. The overall mean percent recovery across 3 lots was 99.4% with an average variation (CV) of 6.1%.

LIMITATIONS OF THE TEST

The Protein C Antigen concentration values obtained from this assay are an aid to diagnosis only. Each physician must interpret these results in light of the patient's history, physical findings, and other diagnostic procedures. Patients with congenital homozygous deficiency of Protein C may have undetectable levels of Protein C, while those with heterozygous deficiency typically have levels between 30% to 60% of normal. Acquired Protein C deficiency may be seen with numerous clinical conditions: neonates (levels 20 - 50% lower than adults), severe liver disease, oral anticoagulant therapy, post-operative period, disseminated intravascular coagulation (DIC), antiphospholipid syndrome, etc.⁶⁻⁸ Increased levels of Protein C may be seen in patients with renal disease.

Plasma samples can be inadvertently depleted or degraded of Protein C by improper collection or laboratory processing.

As with any assay employing antibodies from an animal source (e.g. mouse, rabbit, goat, etc.) to capture a target molecule, the possibility exists for interference in the serum or plasma of patients who have been exposed to preparations containing animal antibodies for diagnosis or therapy. Falsely elevated or depressed values may be seen in these patients.

Warranty

This product is warranted to perform as described in this package insert. Corgenix, Inc. disclaims any implied warranty of merchantability or fitness for a particular use, and in no event shall Corgenix, Inc. be liable for consequential damage.

For Technical or Customer Service in the United States, phone 1-800-729-5661. Outside the United States, phone +303-457-4345, fax +303-457-4519, e-mail: technicalsupport@corgenix.com, or contact a Corgenix authorized distributor.

REFERENCES

1. Kisiel W. Human plasma Protein C. Isolation, characterization, mechanism of activation by α -Thrombin. *J Clin Invest* 64:761-769, 1979.
2. Clouse LH, Comp PC. The regulation of hemostasis: The Protein C System. *N Engl J Med* 314:1298-1304, 1986.
3. Stenflo J. Structure and function of Protein C: *Semin Thromb Haemost* 10:109-121, 1984.
4. Griffin JH, Evatt B, Zimmerman TS, et al. Deficiency of Protein C in congenital thrombotic disease. *J Clin Invest* 68:1370-1373, 1981.
5. Tollefson DFJ, Friedman KD, et al. Protein C Deficiency: A cause of unusual or unexplained thrombosis. *Arch Surg* 123:881-884, 1988.
6. Preissner KT. Biological relevance of the Protein C system and laboratory diagnosis of Protein C and S deficiencies. *Clin Science* 78:351-364, 1990.
7. Griffin JH, Evatt B, Wideman C, et al. Anticoagulant Protein C Pathway defective in majority of thrombophilic patients. *Blood* 82:1989-1993, 1993.
8. Miletich JP. Laboratory diagnosis of Protein C deficiency. *Semin Thromb Haemost* 16:169-176, 1990.
9. Data on File.

SYMBOL LEGEND

											
Manufacturer	Authorized Representative	In vitro diagnostic medical device	Batch Code	Use by/ Expiry Date	Temperature Limitation	Warning	Caution	Biological Risk	Catalog Number	European Conformity	Consult Instructions for Use/ Package Insert
Hersteller	Bevoll-mächtigter	In-vitro-Diagnostikum	Chargennummer	Verfallsdatum	Temperatur-beschränkungen	Waarschuwing	Voorzichtigheid	Biologisches Risiko	Katalognummer	CE-Konformitäts-kennzeichnung	Gebrauchsanweisung im Inneren der Verpackung beachten
Fabriqué par	Représentant agréé	Dispositif de diagnostic in vitro	Code de Lot	Utiliser jusqu' à/ Date de péremption	Limites de température	Avertissement	Prudence	Risque biologique	Numéro de catalogue	Conformité aux normes européennes	Consulter le mode d'emploi/ notice jointe au conditionnement
Fabricado por	Representante autorizado	Dispositivo médico para diagnóstico in vitro	Código de Lote	Usar antes de/ Fecha de caducidad	Limitación de temperatura	Advertencia	Precaución	Riesgo biológico	Número de catálogo	Conformidad europea	Consultar las instrucciones de uso/ prospecto del envase
Prodotta da	Rappresentante autorizzato	Dispositivo medico-diagnostico in vitro	Codice del lotto	Scade il/ data di scadenza	Limite di temperatura	Avvertimento	Cautela	Rischio biologico	Numero di catalogo	Conformità europea	Consultare le istruzioni per l'uso/ il foglietto illustrativo



MT Promedt Consulting GmbH
 Altenhofstraße 80
 D-66386 St. Ingbert/Germany



Corgenix, Inc.
 11575 Main Street, Suite 400
 Broomfield, Colorado 80020, USA
REAADS® is a registered trademark of Corgenix, Inc.
 © 2015, Corgenix, Inc.

13035901 09
 Effective: 2015-08-29